Literature DB >> 25563193

Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma.

Gati Asma1, Gorrab Amal, Marrakchi Raja, Derouiche Amine, Chebil Mohammed, Ben Ammar Elgaaied Amel.   

Abstract

The clear evidence that tumor-infiltrating lymphocytes (TIL) exists in the tumor microenvironment raises the question why renal cell carcinoma (RCC) progresses. Numerous studies support the implication of CD4(+)CD25(high) regulatory T (Treg) cells in RCC development. We aimed in this study to characterize the phenotype and function of circulating and intratumoral Treg cells of RCC patient in order to evaluate their implication in the inhibition of the local antitumor immune response. Our results demonstrate that the proportion of Treg in TIL was, in average, similar to that found in circulating CD4(+) T cells of patients or healthy donors. However, intratumoral Treg exhibit a marked different phenotype when compared with the autologous circulating Treg. A higher CD25 mean level, HLA-DR, Fas, and GITR, and a lower CD45RA expression were observed in intratumoral Treg, suggesting therefore that these cells are effector in the tumor microenvironment. Additionally, intratumoral Treg showed a higher inhibitory function on autologous CD4(+)CD25(-) T cells when compared with circulating Treg that may be explained by an overexpression of FoxP3 transcription factor. These findings suggest that intratumoral Treg could be major actors in the impairment of local antitumor immune response for RCC patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563193     DOI: 10.1007/s13277-014-3012-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

2.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

3.  Regulatory T cells and TGF-β1 in clinically localized renal cell carcinoma: Comparison with age-matched healthy controls.

Authors:  Choung-Soo Kim; Yunlim Kim; Taekmin Kwon; Jong Hyun Yoon; Kwang Hyun Kim; Dalsan You; Jun Hyuk Hong; Hanjong Ahn; In Gab Jeong
Journal:  Urol Oncol       Date:  2014-12-11       Impact factor: 3.498

4.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

5.  Aire-dependent thymic development of tumor-associated regulatory T cells.

Authors:  Sven Malchow; Daniel S Leventhal; Saki Nishi; Benjamin I Fischer; Lynn Shen; Gladell P Paner; Ayelet S Amit; Chulho Kang; Jenna E Geddes; James P Allison; Nicholas D Socci; Peter A Savage
Journal:  Science       Date:  2013-03-08       Impact factor: 47.728

6.  Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.

Authors:  Tricia A Moo-Young; Justin W Larson; Brian A Belt; Marcus C Tan; William G Hawkins; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunother       Date:  2009-01       Impact factor: 4.456

7.  Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.

Authors:  Derek A Wainwright; Sadhak Sengupta; Yu Han; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2011-09-08       Impact factor: 12.300

8.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

9.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  5 in total

Review 1.  Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Authors:  Matthew K Labriola; Kristen A Batich; Jason Zhu; Megan A McNamara; Michael R Harrison; Andrew J Armstrong; Daniel J George; Tian Zhang
Journal:  Clin Genitourin Cancer       Date:  2019-02-05       Impact factor: 2.872

2.  Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.

Authors:  Marina K Baine; Gabriela Turcu; Christopher R Zito; Adebowale J Adeniran; Robert L Camp; Lieping Chen; Harriet M Kluger; Lucia B Jilaveanu
Journal:  Oncotarget       Date:  2015-09-22

Review 3.  Immune consequences of anti-angiogenic therapyin renal cell carcinoma.

Authors:  Klaudia K Brodaczewska; Cezary Szczylik; Claudine Kieda
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

4.  T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production.

Authors:  Saskia D van Asten; Rosa de Groot; Marleen M van Loenen; Suzanne M Castenmiller; Jeroen de Jong; Kim Monkhorst; John B A G Haanen; Derk Amsen; Axel Bex; Robbert M Spaapen; Monika C Wolkers
Journal:  Oncoimmunology       Date:  2021-01-21       Impact factor: 8.110

Review 5.  New emerging targets in cancer immunotherapy: the role of GITR.

Authors:  Giulia Buzzatti; Chiara Dellepiane; Lucia Del Mastro
Journal:  ESMO Open       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.